1.48
0.02 (1.37%)
| Previous Close | 1.46 |
| Open | 1.49 |
| Volume | 251,705 |
| Avg. Volume (3M) | 408,828 |
| Market Cap | 215,291,168 |
| Price / Sales | 2.58 |
| Price / Book | 7.62 |
| 52 Weeks Range | |
| Earnings Date | 27 Feb 2025 - 3 Mar 2025 |
| Profit Margin | -66.84% |
| Operating Margin (TTM) | -47.33% |
| Diluted EPS (TTM) | -0.370 |
| Quarterly Revenue Growth (YOY) | 34.50% |
| Total Debt/Equity (MRQ) | 226.08% |
| Current Ratio (MRQ) | 3.40 |
| Operating Cash Flow (TTM) | -56.84 M |
| Levered Free Cash Flow (TTM) | -43.44 M |
| Return on Assets (TTM) | -22.79% |
| Return on Equity (TTM) | -331.82% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Mixed | Mixed |
| Diagnostics & Research (Global) | Mixed | Mixed | |
| Stock | Biodesix, Inc. | Mixed | Bearish |
AIStockmoo Score
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 2.0 |
| Average | 0.83 |
|
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing services associated with blood-based lung and Coronavirus Disease 2019 (COVID-19) tests; and providing biopharmaceutical companies with services generally provided outside the clinical setting and governed by individual contracts with third parties as well as development and commercialization of companion diagnostics. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 48.62% |
| % Held by Institutions | 42.83% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Wilmington Savings Fund Society, Fsb | 30 Sep 2024 | 6,095,034 |
| Birchview Capital, Lp | 30 Sep 2024 | 5,541,176 |
| Silverarc Capital Management, Llc | 30 Sep 2024 | 3,561,094 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 Nov 2024 | Announcement | Biodesix Announces Third Quarter 2024 Results and Highlights |
| 29 Oct 2024 | Announcement | Biodesix to Participate in Three Investor Conferences in November |
| 18 Oct 2024 | Announcement | Biodesix to Report Third Quarter 2024 Financial Results on November 1, 2024 |
| 07 Oct 2024 | Announcement | Biodesix Announces New Data Presentation at CHEST 2024 Annual Meeting and the Launch of a Complementary Clinical Study |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |